Please login to the form below
Tregs
This page shows the latest Tregs news and features for those working in and with pharma, biotech and healthcare.
Merck to acquire Pandion Therapeutics for $1.85bn
Leading Pandion’s pipeline is an engineered IL-2 mutein fused to a protein backbone – known as PT101 – that is designed to selectively activate and expand regulatory T cells (Tregs) for ... Tregs can inhibit the activity of several different
Latest news
-
Syncona start-up Quell Therapeutics appoints chief exec
Biotech focusing on Tregs. Quell Therapeutics, a new UK biotech company focused on developing engineered T regulatory (Treg) cell therapies, has appointed Iain McGill as its chief executive. ... London-based Quell Therapeutics aims to harness this
-
Syncona launches another cell therapy company, Treg specialist Quell
Tregs – which have the potential to downregulate the immune system – have clear potential in this area. ... Similarly, Lilly/Nektar’s NKTR-358 also targets the IL-2 receptor complex to stimulate Treg production.
-
Genentech forges $800m autoimmune alliance with Parvus
regulatory T cells specific to the patient’s disease.” “Referred to as disease- or tissue-specific T regulatory cells (Tregs), these cells induce immunological tolerance to block undesired immune responses to
-
AbbVie to develop argenx-partnered GARP-targeted immunotherapy
β). The companies have said that ARGX-115 will selectively limit the activity of activated regulatory T-cells (Tregs). ... While the normal function of Tregs is to suppress certain compartments of the immune system to prevent self-directed immune
-
Sangamo bulks up in cell therapy with TxCell acquisition
generation autologous and allogeneic CAR-Treg cell therapies for use in treating autoimmune diseases.”. ... We believe CAR-Treg therapies will prove to be as exciting for immunology as CAR-T has been for oncology.”.
More from news
Approximately 1 fully matching, plus 7 partially matching documents found.
Latest Intelligence
-
Deal Watch October 2018
Although described as an acquisition, the deal covers two products, including an anti-CD25 antibody that depletes regulatory T‐cells (Tregs) while preserving IL‐2 binding and signalling on effector ... Tregs) while preserving effector T‐cells (Teffs
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest appointments
-
TxCell appoints François Myer as executive chairman
French biotech company TxCell has appointed François Meyer as its executive chairman as it completes a strategic realignment around its CAR-Treg research programmes. ... We can now look to the future with great expectations and with one major objective
-
Dr Li Zhou joins TxCell as cell engineering VP
Dr Zhou will lead the team's discovery and engineering activities on Chimeric Antigen Receptor in Treg cells ( CAR-Treg) for immunotherapy of severe chronic autoimmune and inflammatory diseases and organ ... Cell engineering significantly broadens the
-
TxCell appoints global scientific advisory board
leadership in the promising field of Treg Cells.
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest from PMHub
-
Parachuting Behind Enemy Lines: OncoSec’s Attack on Visceral Tumors via Its New Visceral Lesion Applicator (VLA)
For example, the relevant immune mechanisms associated with clinical progression of HCC include increased tumor-infiltrating regulatory T cells (Tregs) and M2-polarized tumor-associated macrophages (TAMs), which can establish immune ... TILs) to Tregs as
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Scientific Director, MRNA/ Covid 19, Medical Communications, UK
-
Six figure salary
-
B2B media account director
-
Competitive salary
- Vaccines writer – career opportunity to move into medcomms from ...
-
Highly competitive salary
- Principal Medical Writer, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Senior Account Exec > CSD – Medical Communications – UK, Lond...
-
Highly Competitive Salary, Bonus &Benefits
- Medical Writers > Scientific Directors – Medical Communicatio...
-
Highly Competitive Salary, Bonus &Benefits
- AstraZeneca blocks take-private buyout of Sobi
- Lilly’s combination antibody expanded to children under 12
- Working with purpose and putting talent development at the heart of operations
- A Lucid Thirsty Thursday D&I Special
- Diversity in clinical trials: looking back at our 2021 blogs
- MHRA approves second COVID-19 antibody treatment
- First trial of a vaccine against Alzheimer’s launches
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- Bristol Myers Squibb announces data on Zeposia from DAYBREAK study in MS
- Pfizer's 2021 revenue predictions soar to $82bn
- Sinovac’s COVID-19 vaccine appears safe in older adults
- Vertex moves ahead with its bid to develop a curative treatment for type 1 diabetes
PMHub
W2O Group
W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...
Latest intelligence
- Diversity in clinical trials: looking back at our 2021 blogs
- In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
- What does the future hold for Light-chain Amyloidosis?
- Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
- Webinar:
- Securing a future for telehealth with immersive market research insights...
